GlassScriptPhysician profile
Stephanie Dang
NPI 1376897546
$6,163.69
in general payments reported to CMS, 2019-2025
22 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $607 · 2023: $1,159 · 2024: $1,812 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,139 · Education: $16.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,138.75 |
| Education | $16.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,102.96 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $832.60 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $603.42 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $434.92 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $409.20 | 2024-2025 | Fanapt |
| Amgen INC. | $280.28 | 2024 | Krystexxa, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $270.07 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $238.14 | 2024-2025 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $231.84 | 2021-2025 | Trintellix |
| Tms Neurohealth Centers INC. | $203.28 | 2025 | Tms Neurohealth Centers INC. |
| Lundbeck LLC | $187.90 | 2022-2025 | Rexulti |
| Horizon Therapeutics Plc | $187.03 | 2022-2023 | Krystexxa |
| Supernus Pharmaceuticals, INC. | $158.29 | 2025 | Qelbree |
| Averitas Pharma INC. | $149.98 | 2025 | Qutenza |
| Genentech USA, INC. | $137.01 | 2023 | Ocrevus |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $123.38 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $113.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $110.89 | 2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $104.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $103.11 | 2025 | Voquezna |
| Corcept Therapeutics | $102.30 | 2024 | Korlym |
| Teleflex LLC | $78.36 | 2024 | Urolift |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.